Managing Heyde Syndrome: From Aortic Valves to Endoscopic Intervention

Heyde syndrome represents one of the most fascinating intersections between cardiology and gastroenterology, where aortic stenosis leads to gastrointestinal bleeding through acquired von Willebrand disease. Understanding the full spectrum of management options is crucial for optimizing patient outcomes in this complex condition.

The Expanding Spectrum of Heyde Syndrome

What we’ve learned over the years is that Heyde syndrome extends beyond the classic presentation of aortic stenosis with small bowel angiodysplasia. We now recognize this as part of a broader spectrum that includes patients with left ventricular assist devices (LVADs) and even gastric vascular malformations. The underlying mechanism remains the same: high shear stress leading to degradation of von Willebrand factor multimers, which then predisposes to bleeding from angiodysplastic lesions throughout the GI tract.

Surgical Management: The Gold Standard

Aortic valve replacement remains the definitive treatment for classic Heyde syndrome. The Mayo Clinic studies I referenced earlier demonstrate that successful valve replacement can cure many of these patients. However, the key word here is “successful.” The prosthetic valve must function well and significantly reduce the gradient for patients to see resolution of their bleeding.

The data on transcatheter aortic valve replacement (TAVR) is more mixed. While some studies show improvement in von Willebrand factor multimers after TAVR, clinical bleeding outcomes haven’t been as consistently successful as with surgical valve replacement. This may reflect that some patients already have established bowel lesions that continue to bleed despite correction of the underlying coagulopathy.

Interestingly, we’ve also seen improvement in patients with hypertrophic obstructive cardiomyopathy who undergo septal reduction procedures. This reinforces that the common denominator is eliminating high-gradient flow states, whether from aortic stenosis, LVOT obstruction, or hypertrophic cardiomyopathy.